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The aim of the present study was to examine the association between daily omega-3 fatty acid intake and depression in Japanese
cancer patients. Omega-3 fatty acid intake in 771 patients with newly diagnosed primary lung cancer was evaluated using a food-
frequency questionnaire, and the prevalence of depression was examined using the cutoff values for the depression subscale included
in the Hospital Anxiety and Depression Scale. After adjustment for potential confounding factors, the odds ratio (OR) for depression
among patients in the highest quartile of the total eicosapentaenoic acid- (C20:5n-3) and docosapentaenoic acid (C22:6n-3)-intake
group compared with patients in the lowest quartile was not significantly different. On the other hand, the OR among the highest
quartile of a-linolenic acid (C18:3n-3) intake (adjusted OR¼0.50, 95% CI: 0.31– 0.71, P for trend¼0.004) and the highest quartile of
total omega-3 fatty acid intake (adjusted OR¼0.55, 95% CI: 0.35–0.88, P for trend¼0.022) were significantly different. These results
suggest that total eicosapentaenoic acid and docosapentaenoic acid intake might not be associated with depression in Japanese
patients with newly diagnosed lung cancer, but that a-linolenic acid intake and total omega-3 fatty acid intake might be.
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Depression is the most common psychiatric problem in clinical
oncology settings, with around 20% of cancer patients experien-
cing depression (McDaniel et al, 1995; Massie and Popkin, 1998).
Depression influences the quality of life of cancer patients and
often leads to a poor compliance with cancer treatment and
suicidal ideation or suicide (Grassi et al, 1996; Breitbart et al, 2000;
Colleoni et al, 2000; Akechi et al, 2002). Antidepressants are the
only well-established treatment for depression in cancer patients
(Gill and Hatcher, 1999); however, antidepressant therapy is
difficult to perform in cancer patients, because the adverse effects
of antidepressants might overload the patient’s physical condition
(Akizuki et al, 2002). Thus, a novel medication with few adverse
effects is needed for the management of depression in cancer
patients.
Recent psychiatry studies have investigated the association
between depression and omega-3 fatty acids (o-3 FAs), a
potentially natural and tolerable antidepressant. Omega-3 fatty
acids, which have a double bond at the third carbon from the
methyl end of the molecule, include eicosapentaenoic acid (EPA;
C20:5n-3) and docosahexaenoic acid (DHA; 22:6n-3), which are
derived from fish and seafood, and a-linolenic acid (a-LA; C18:3n-
3), which is derived from plant sources. Humans lack the
desaturase enzyme, so o-3 FAs cannot be formed in the body;
thus, dietary intake is the only source of o-3 FAs. The depletion of
cell membrane o-3 FAs has been hypothesised to be of aetiologic
importance in depression (Smith, 1991; Hibbeln and Salem, 1995;
Maes and Smith, 1998).
Some clinical evidence has supported the hypothesis that low
levels of o-3 FAs may be implicated in depression. Epidemiolo-
gical findings linking depression and low levels of fish intake have
been reported (Hibbeln, 1998; Tanskanen et al, 2001), and
biochemical research has also shown that the concentrations of
each o-3 FA are significantly lower in the serum or red blood cell
membranes of depressed patients than in control subjects
(Edwards et al, 1998; Peet et al, 1998; Maes et al, 1999). Ethyl-
EPA augmentation therapy has been reported to improve
depressive symptoms in patients with major depression in
randomised placebo-controlled double-blind clinical trials
(Nemets et al, 2002; Peet and Horrobin, 2002) and in one clinical
report (Puri et al, 2002). These trials have also reported no or a few
adverse effects of the medication (e.g. mild gastrointestinal tract
distress). In addition, the antidepressive effect of o-3 FAs has also
been reported in patients with other psychiatric conditions,
including depression in pregnant woman (Chiu et al, 2003),
borderline personality disorder (Zanarini and Frankenburg, 2003),
and bipolar disorder (Stoll et al, 1999). This clinical evidence
suggests that the administration of o-3 FAs, especially EPA or
DHA, may be useful for the management of depression in various
situations.
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lAs a preliminary examination of the utility of administering o-3
FAs for the treatment or prevention of depression in cancer
patients, we performed a cross-sectional study on the relationship
between the daily intake of each o-3 FA (as calculated using a
food-frequency questionnaire (FFQ)) and the prevalence of
depression in newly diagnosed Japanese patients with lung cancer.
We hypothesised that a high intake of EPA and DHA may be
associated with a low prevalence of depression.
METHODS
Subjects
This study was approved by the Institutional Review Board and the
Ethics Committee of the National Cancer Center, Japan.
Data from subjects who participated in The Lung Cancer
Database Project at the National Cancer Center Hospital East
and the National Cancer Center Research Institute East were
used in the present study. The aim of The Lung Cancer Database
Project is to construct a comprehensive database of information
that can be used to investigate the pathogenesis of lung cancer
and improve currently available treatments. The database includes
information on demographic factors, physical symptoms,
psychological factors, and lifestyle factors (diet, smoking, etc)
obtained from self-reported questionnaires and medical informa-
tion from the patients’ medical charts and blood, DNA, and urine
specimens.
The subjects enrolled in the present study were all newly
diagnosed patients with primary lung cancer, who visited the
Thoracic Oncology Division of the National Cancer Center
Hospital East, Japan. Patients were included in this database study
if they met all of the following criteria: informed of their lung
cancer diagnosis; lung cancer diagnosis confirmed by histological
examination; physically capable of completing the questionnaires;
absence of cognitive impairment, such as dementia and delirium;
ability to provide written consent; no problems regarding the
patients’ participation in this database study, as judged by their
physicians.
Study procedure
Between July 1999 and November 2001, consecutive patients
eligible for The Lung Cancer Database Project were recruited after
the disclosure of their diagnosis by their attending physician. The
patients completed the questionnaires during the waiting period
prior to admission, and the questionnaires were collected after the
patients were admitted. All patients provided their written
informed consent prior to enrolment in this project.
Measurement of depression
We used the Hospital Anxiety and Depression Scale (HADS)
(Zigmond and Snaith, 1983), which consists of a seven-item
anxiety subscale and a seven-item depression subscale to assess the
anxiety and depressive symptoms during the preceding week in
medically ill patients. The HADS has been used as a reliable and
valid method of screening for depression in patients with cancer
(Razavi et al, 1990; Hopwood et al, 1991; Patrick et al, 2003). Each
item is rated on a scale of 0–3, with higher scores denoting a
greater mood disturbance. The reliability and validity of the
Japanese version of this questionnaire has been established in
Japanese cancer patients (Kugaya et al, 1998). In this study,
depression was evaluated using the depression subscale (HADS-D)
with a cutoff point of 4/5, since this cutoff point has been found to
yield a good sensitivity and specificity (91.5 and 58.0%,
respectively) (Kugaya et al, 1998) for the screening of depression
(adjustment disorder and major depression).
Assessment x-3 FA intake
The semiquantitative FFQ was made for a population-based
prospective study in Japan (Tsubono et al, 1996), and contains
questions regarding 138 foods (including 18 fish and seafood
items). For each food item, the participants reported the average
frequency of consumption during the preceding year prior to the
onset of their cancer symptoms and specified the usual serving
size. Nine responses were possible for each food item, ranging
from ‘never’ to ‘7 or more times per day’. The average daily intake
of nutrients was calculated by multiplying the frequency of the
consumption of each item by its nutrient content per serving and
totalling the nutrient intake for all food items. The method used to
calculate the average daily intake of each food and nutrient based
on the FFQ responses has been described elsewhere (Sasaki et al,
2003).
The o-3 FA family includes a-LA (C18:3n-3), octadecatetraenoic
acid (C18:4n-3), eicosatetraenoic acid (C20:4n-3), EPA (C20:5n-3),
docosapentaenoic acid (DPA; C22:5n-3), and DHA (22:6n-3). We
calculated the intake of each of these compounds, the total EPA
and DHA intake, and the total o-3 FA intake. The Fatty Acid
Composition Table of Japanese Foods (Science and Technology
Agency of Japan, 1990) was used to calculate the daily intake of
each o-3 FA. Since the table has missing values for some foods, we
substituted the fatty acid composition of the missing foods (Sasaki
et al, 1999).
The validity of the FFQ was assessed in a random sample of 102
men and 113 women living in four areas of Japan by comparing the
data from the FFQ with the data from 14–28 dietary records
collected approximately 6 months apart. The Spearman rank
correlation coefficients for an association between the data from
the FFQ and the dietary records for the men and women were 0.26
(95% CI, 0.04–0.48) and 0.28 (0.13–0.44), for the total o-3 FAs
intake (energy-adjusted values according to energy density),
respectively, 0.32 (0.16–0.48) and 0.20 (0.05–0.34) for a-LA
intake; 0.40 (0.09-0.72) and 0.47 (0.34–0.60) for octadecatetraenoic
acid intake; 0.27 ( 0.06–0.6) and 0.30 (0.17–0.44) for eicosate-
traenoic acid intake; 0.38 (0.09–0.67) and 0.41 (0.26–0.56) for EPA
intake; 0.36 (0.05–0.67) and 0.35 (0.22–0.49) for DPA intake; and
0.34 (0.07–0.61) and 0.36 (0.21–0.51) for DHA intake.
Assessment of demographical and medical factors
Demographic factors (age, gender, education level, employment
status, marital status, smoking, and drinking habits) and medical
factors (histology, clinical stage, and symptoms) were obtained
from the self-reported questionnaires and the patients’ medical
charts. Performance status (PS) was assessed by each attending
physician using the Eastern Cooperative Oncology Croup criteria.
Statistical analyses
Odds ratios were calculated by dividing the prevalence of
depression in each of four equal quartile groups (grouped
according to the intake of each o-3 FA) by the prevalence of
depression in the lowest quartile of o-3 FA intake. The same
analysis was conducted using quartiles grouped according to total
o-3 FA intake and total EPA and DHA intake. A logistic-regression
analysis, with adjustments for sex and age in 10-year groupings,
was then performed; simultaneously, pain (present/absent) and
performance status (0/1–4) were used as factors well known to be
strongly associated with depression in cancer patients, and
smoking status (current-smoker/ex-smoker/nonsmoker) and
amount of alcohol consumption were used as factors thought to
influence o-3 FA metabolism (Simon et al, 1996; Pawlosky
and Salem, 1999). Some background variables that were
significantly associated with depression in this sample, according
to a bivariate analysis (w
2 test), were also included; histology
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breathlessness (present/absent), and employment status (em-
ployed/unemployed) (Table 1). We also tested for significant
trends by assigning each patient the median value of their category
and modelling it as a continuous variable.
A P-value of o0.05 was considered to be statistically significant;
all tests were two-tailed. All statistical analyses were performed on
a personal computer using the statistical software package SPSS for
Windows (Version 11.0J, SPSS Japan Institute Inc.).
RESULTS
Participants
In total, 1013 patients with newly diagnosed, untreated primary
lung cancer were admitted during The Lung Cancer Database
Project enrolment period. A total of 42 patients were ineligible, the
most common reason for exclusion being that the patient’s
condition was too poor for the patient to participate in the
project. Of the remaining 971 eligible patients, 30 refused to
Table 1 Patients’ characteristics
HADS-D
a
p4( n¼335) X5( n¼436)
Variable n (%) n (%) P-value
Age (mean7s.d. years) 64.0 (9.5) 64.3 (9.1) 0.651
Sex Female 93 (27.8) 122 (28.0) 0.946
Education p9years 101 (30.1) 136 (31.2) 0.705
Marital status Married 280 (83.6) 370 (84.9) 0.669
Employment status Full & part time 151 (45.1) 152 (34.9) 0.004
Histology
Adenocarcinoma 221 (66.0) 240 (55.0) 0.003
Squamous 67 (20.0) 87 (20.0)
Small 20 (6.0) 57 (13.1)
Large 21 (6.3) 36 (8.3)
Others 6 (1.8) 16 (3.7)
Clinical stage
b
Ia 111 (33.1) 72 (16.5) 0.000
Ib 59 (17.6) 64 (14.7)
IIa 4 (1.2) 7 (1.6)
IIb 15 (4.5) 28 (6.4)
IIIa 19 (5.7) 42 (9.6)
IIIb 49 (14.6) 93 (21.3)
IV 78 (23.3) 130 (29.8)
Performance status
c
0 168 (50.1) 141 (32.3) 0.000
1 161 (48.1) 261 (59.9)
2 6 (1.8) 24 (5.5)
3 0 (0.0) 10 (2.3)
4 0 (0.0) 0 (0.0)
Symptoms
Breathlessness (presence) 102 (30.4) 226 (51.8) 0.000
Pain (presence) 86 (25.7) 176 (41.4) 0.000
Smoking
Current smoker 179 (53.4) 244 (56.0) 0.444
Ex-smoker 66 (19.7) 91 (20.9)
Nonsmoker 87 (26.0) 97 (22.2)
Total energy intake (kcal) 181971534 18157529 0.919
Total fat intake (% of energy) 26.276.8 25.676.7 0.192
Omega-3 fatty acid intake (% of energy)
a-LA intake (C18:3n-3) 0.9370.30 0.8670.30 0.002
Octadecatetraenoic acid intake (C18:4n-3) 0.0470.02 0.0370.02 0.375
Eicosatetraenoic acid intake (C20:4n-3) 0.0270.01 0.0270.01 0.361
Eicosapentaenoic acid intake (C20:5n-3) 0.1670.09 0.1670.10 0.364
Docosapentaenoic acid intake (C22:5n-3) 0.0470.02 0.0470.03 0.459
Docosahexaenoic acid intake (C22:6n-3) 0.2870.14 0.2770.15 0.372
Docosahexaenoic acid and eicosapentaenoic acid intake 0.4570.23 0.4370.24 0.367
Total omega-3 fatty acid intake 1.5270.47 1.4370.48 0.013
aHADS-D: Depression subscale of the Hospital Anxiety and Depression Scale.
bDefined by TNM classification: International Union Against Cancer.
cDefined by the Eastern
Cooperative Oncology Group.
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lTable 2 Odds ratio of depression according to quartiles of omega-3 fatty acids intake (% energy) by the lung cancer patients (n¼771)
HADS-D
a Odds ratio
p4 X5 Crude Adjusted for age and sex Multivariate
b
Median Intake (% energy) n (%) (95% CI)
c
Quartiles of a-linolenic acid intake (C18:3n-3)
q
1 0.552 68 (35.4) 124 (64.6) 1.00 1.00 1.00
q
2 0.776 80 (41.5) 113 (58.5) 0.78 (0.51–1.17) 0.76 (0.50–1.15) 0.68 (0.43–1.07)
q
3 0.982 93 (48.2) 100 (51.8) 0.59 (0.39–0.89) 0.56 (0.37–0.85) 0.55 (0.34–0.87)
q
4 1.223 94 (48.7) 99 (51.3) 0.58 (0.38–0.87) 0.54 (0.35–0.82) 0.50 (0.31–0.71)
P for trend 0.004 0.002 0.004
Quartiles of octadecatetraenoic acid intake (C18:4n-3)
q
1 0.015 71 (40.0) 121 (60.0) 1.00 1.00 1.00
q
2 0.024 83 (43.0) 110 (57.0) 0.78 (0.52–1.17) 0.78 (0.52–1.18) 0.72 (0.46–1.13)
q
3 0.034 96 (49.7) 97 (50.3) 0.59 (0.40–0.89) 0.58 (0.39–0.88) 0.61 (0.40–0.95)
q
4 0.062 85 (44.0) 108 (56.0) 0.75 (0.50–1.12) 0.74 (0.49–1.13) 0.83 (0.53–1.30)
P for trend 0.250 0.250 0.721
Quartiles of eicosatetraenoic acid intake (C20:4n-3)
q
1 0.008 75 (39.1) 117 (60.9) 1.00 1.00 1.00
q
2 0.001 81 (42.0) 112 (58.0) 0.89 (0.59–1.33) 0.89 (0.59–1.34) 0.88 (0.57–1.36)
q
3 0.017 97 (50.3) 96 (49.7) 0.63 (0.42–0.95) 0.64 (0.42–0.95) 0.63 (0.41–0.97)
q
4 0.027 82 (42.5) 111 (57.5) 0.87 (0.58–1.30) 0.86 (0.57–1.30) 0.97 (0.62–1.51)
P for trend 0.434 0.409 0.864
Quartiles of eicosapentaenoic acid intake (C20:5n-3)
q
1 0.074 78 (40.6) 114 (59.4) 1.00 1.00 1.00
q
2 0.115 77 (39.9) 116 (60.1) 1.03 (0.69–1.55) 1.05 (0.70–1.58) 0.99 (0.64–1.55)
q
3 0.165 95 (49.2) 98 (50.8) 0.71 (0.47–1.06) 0.69 (0.46–1.04) 0.55 (0.42–1.01)
q
4 0.265 85 (44.0) 108 (56.0) 0.87 (0.58–1.30) 0.86 (0.57–1.30) 0.99 (0.64–1.55)
P for trend 0.332 0.312 0.849
Quartiles of docosapentaenoic acid intake (C22:5n-3)
q
1 0.020 75 (39.1) 117 (60.9) 1.00 1.00 1.00
q
2 0.032 82 (42.5) 111 (57.5) 0.87 (0.58–1.30) 0.88 (0.58–1.32) 0.88 (0.57–1.36)
q
3 0.454 91 (47.2) 102 (52.8) 0.72 (0.48–1.01) 0.72 (0.48–1.08) 0.70 (0.45–1.08)
q
4 0.704 87 (45.1) 106 (54.9) 0.78 (0.52–1.17) 0.77 (0.51–1.17) 0.88 (0.57–1.36)
P for trend 0.218 0.197 0.556
Quartiles of docosahexaenoic acid intake (22:6n-3)
q
1 0.140 74 (38.5) 118 (61.5) 1.00 1.00 1.00
q
2 0.206 82 (42.5) 111 (57.5) 0.85 (0.57–1.28) 0.86 (0.57–1.30) 0.95 (0.61–1.47)
q
3 0.290 93 (48.2) 100 (51.8) 0.67 (0.45–1.01) 0.67 (0.44–1.00) 0.60 (0.38–0.93)
q
4 0.435 86 (44.6) 107 (55.4) 0.78 (0.52–1.17) 0.77 (0.51–1.17) 0.94 (0.60–1.47)
P for trend 0.216 0.199 0.584
Quartiles of Total omega-3 fatly acid intake
q
1 0.943 67 (34.9) 125 (65.1) 1.00 1.00 1.00
q
2 1.275 87 (45.1) 106 (54.9) 0.65 (0.43–0.99) 0.63 (0.42–0.96) 0.63 (0.40–0.99)
q
3 1.603 86 (44.6) 107 (55.4) 0.67 (0.44–1.01) 0.64 (0.42–0.97) 0.61 (0.38–0.97)
q
4 2.007 95 (49.2) 98 (50.8) 0.55 (0.37–0.83) 0.52 (0.34–0.80) 0.55 (0.35–0.88)
P for trend 0.008 0.005 0.022
Quartiles of sum of eicosapentaenoic and docosahexaenoic acid intake
q
1 0.217 76 (39.6) 116 (60.4) 1.00 1.00 1.00
q
2 0.322 79 (40.9) 114 (59.1) 0.95 (0.63–1.42) 0.96 (0.64–1.44) 1.00 (0.65–1.56)
q
3 0.456 94 (48.7) 99 (51.3) 0.69 (0.46–1.03) 0.68 (0.45–1.02) 0.64 (0.41–0.98)
q
4 0.700 86 (44.6) 107 (55.4) 0.82 (0.54–1.22) 0.81 (0.54–1.22) 0.96 (0.61–1.49)
P for trend 0.237 0.221 0.648
aHADS-D: Depression subscale of the Hospital Anxiety and Depression Scale.
bAdjusted for age, sex, performance status, clinical stage, histology, pain, breathlessness,
employment, smoking, alcohol consumption, and body mass index as covariates.
c95% confidence interval.
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lparticipate in this study and 39 could not be contacted (e.g.,
because of emergency admission and the immediate start of
treatment). As a result, 902 patients were enrolled in the project.
After excluding the patients who did not complete the HADS-D
(n¼73) or who did not answer the FFQ (n¼62), or who provided
inappropriate answers to the FFQ (a total energy intake of below
900kcalday
 1 or above 4000kcalday
 1 in men or below
800kcalday
 1 or above 3600kcalday
 1 in women, n¼24), a total
of 771 patients were eligible for analysis. No significant gender
differences were observed between the subjects who were analysed
(n¼771 patients) and the subjects who were not (n¼242
patients). The analysed subjects were younger than the subjects
who were not analysed (P¼0.010), their disease was in clinical
stage Ia-IIb (P¼0.007), and they had a better PS (P¼0.004).
Among the 771 analysed patients, total o-3 FA intake was
primarily from vegetable oils and fats (37% of the total intake)
and secondarily from 17 types of fish (35%), soybean products
(11%), seasonings (5%), and cereals (4%). The proportional daily
intake of o-3 FAs consisted of 62% a-LA, and 20% DHA and 11%
EPA.
Depression and x-3 FA intake
Of the 771 patients analysed, 436 patients (56.5%). had depression
(Table 1).
The crude odds ratio for depression among patients in the
highest quartile of the total EPA and DHA intake was 0.82 (95% CI
0.54–1.22) compared with patents in the lowest quartile, and the
adjusted odds ratio after controlling for possibly associated factors
was 0.96 (95% CI 0.61–1.49); no significant trend in the odds
ratios for depression was observed with regard to total EPA and
DHA intake (P for trend¼0.648, Table 2 and Figure 1). No
significant negative association was found between either EPA
intake or DHA intake and depression (EPA: adjusted odds
ratio¼0.99, 95% CI: 0.64–1.55, P for trend¼0.849; DHA: adjusted
odds ratio¼0.94, 95% CI: 0.60–1.47, P for trend¼0.584).
The crude odds ratio for depression among patients in the
highest quartile of a-LA intake group was 0.58 (95% CI 0.38–0.87)
compared with patents in the lowest quartile, and the adjusted
odds ratio after controlling for the possibly associated factors was
0.50 (95% CI 0.31–0.71); a significant trend in the odds ratio for
depression was observed with regard to total o-3 FA intake (P for
trend¼0.004, Table 2 and Figure 1). A significant negative
association was also found between total o-3 FA intake and
depression (crude odds ratio¼0.55, 95% CI: 0.37–0.83, P for
trend¼0.008; adjusted odds ratio¼0.55, 95% CI: 0.35–0.88, P for
trend¼0.022). In addition, we performed the same analysis for 786
subjects including subjects whose answers were regarded as
indicating an extremely low caloric intake (below 900kcalday
 1
in men or below 800kcalday
 1 in women, n¼15), since it was
impossible to discount the possibility that those patients may have
had a low caloric intake for a variety of reasons (e.g., chronic
depression). The results of this analysis were similar to the
previously obtained results (data not shown).
No association between depression and the intake of fish and
seafood was observed (adjusted OR¼0.81, 95% CI: 0.52–1.26, P
for trend¼0.285, Table 3).
DISCUSSION
This report is the first cross-sectional study to investigate the
association between dietary o-3 FA intake, as calculated using FFQ
data, and the prevalence of depression among cancer patients.
Inconsistent with the results of a previous epidemiological study,
we did not observe a significant association between total DHA
and EPA intake and the prevalence of depression in newly
diagnosed patients with lung cancer. This finding suggests that
DHA and EPA intake may not contribute to a susceptibility to
depression among Japanese cancer patients. Since the standard
Japanese diet contains larger amounts of fish than the diets of
Europeans or Americans, the antidepressive effect of DHA and
EPA may not be apparent in our sample. Another possible reason
for the discrepancy in findings is that the characteristics of
depression in this study may differ from those of previous studies.
Previous epidemiological research examined the prevalence of
depression in the general population (Hibbeln, 1998; Tanskanen
et al, 2001), while we examined depression among a population
that was subjected to the stress of having recently been diagnosed
with lung cancer. Thus, differences in the situations of the subjects
may have caused the inconsistent findings. In addition, our results
must be interpreted with caution, because our sample size was
smaller than that of previous epidemiological studies.
Interestingly, a significant inverse dose–response relationship
was observed between a-LA or total o-3 FA intake and the
prevalence of depression. To the best of our knowledge, this is one
of the first clinical reports to demonstrate an association between
a-LA intake and depression (see Rudin (1981) for a case report).
Although the present study has a cross-sectional design, prevent-
ing us from making any conclusions as to the causality of o-3 FA
intake and depression, it seemed unlikely that depression would
change the intake of o-3 FA. In the present study, no significant
differences in total caloric intake and total fat intake were found
between patients with depression and those without (Table 1). Our
results suggest that low levels of a-LA or total o-3 FA intake may
contribute to a susceptibility to depression. A further clinical trial
using supplements or a special diet is needed to clarify the
independent effects of each o-3 FA on depression.
a-Linolenic acid intake is known to have an influence on the
fundamental structural and functional roles in the developing and
mature nervous system (Bourre et al, 1993; Uauy et al, 1996), and
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Figure 1 Odds ratio for depression in Japanese patients with newly
diagnosed lung cancer categorised by quartile of o-3 FAs intake (n¼771).
Adjusted for age, sex, performance status, clinical stage, histology, pain,
breathlessness, employment, smoking, alcohol consumption, and body mass
index. The widths of the bars represent 95% confidence intervals.
Significant inverse relationship was observed between total o-3 FA or a-
linolenic acid and depression. a-LA, a-linolenic acid; EPA, eicosapentaenoic
acid; DHA, docosahexaenoic acid.
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been observed in animal experiments (Delion et al, 1996).
a-Linolenic acid may influence depression via a mechanism that
is different from that of DHA or EPA. Another possibility is that
the total o-3 FA (including a-LA) intake may reflect the
concentration of DHA and EPA in the body or brain, rather than
the sum of EPA and DHA intake only, since a-LA is the main
source of o-3 FA in the diet and can be converted into DHA or
EPA in humans. Further investigation of a specific o-3 FA
biomarker is needed to confirm this speculation.
Our study has several limitations. First, a sampling bias was
present in the data because all of the subjects attended a single
institution and thus were not representative of lung cancer patients
in general. Second, their possibility of a selection bias should be
considered, since we did not have data on approximately 20% of
the potentially eligible patients and the analysed subjects had a
relatively better PS, an earlier clinical stage, and were younger than
the nonanalysed subjects. Third, since only lung cancer patients
who had been informed of their diagnosis but had not yet started
their cancer treatment were included in the study, the results may
not be applicable to other cancer patients and other cancer
settings. Fourth, we used a self-administered questionnaire to
evaluate o-3 FA intake because a large sample of patients was
needed for The Lung Cancer Database Project. The data obtained
from the FFQ may not reflect the actual o-3 FA intake as
accurately as other more detailed methods, such as dietary records.
Fifth, we did not use a structured psychiatric interview in this
study (such as the Structured Clinical Interview for DSM-IV, a
widely recognized standard). However, HADS has been shown to
be reliable and valid for the screening of depression in patients
with cancer (Razavi et al, 1990; Hopwood et al, 1991), and is widely
used in the field of oncology (Patrick et al, 2003). Finally, a causal
relationship between o-3 FA intake and depression cannot
be confirmed, because of the cross-sectional design of this
study. To clarify the independent effects of each o-3 FA on
depression, a further clinical trial using supplements or a special
diet is needed.
In conclusion, we did not observe a significant relationship
between total EPA and DHA intake and depression in newly
diagnosed Japanese patients with lung cancer, but significant
inverse relationships between a-LA intake or total o-3 FA intake
and depression were noted. Our findings suggest that EPA and
DHA may be of little use as an antidepressant in Japanese cancer
patients. However, the association between a-LA intake or total o-
3 FA intake and depression should be further investigated. To
elucidate the association between each o-3 FA and depression in
patients with cancer, further clinical research (including the
examination of specific biomarkers) is needed.
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